학술논문

Circulating glucagon-like peptide-1 level in patients with liver cirrhosis.
Document Type
Article
Source
Archives of Physiology & Biochemistry. Apr2023, Vol. 129 Issue 2, p373-378. 6p.
Subject
*CIRRHOSIS of the liver
*LIVER diseases
*PANCREATIC beta cells
*ASCITIC fluids
*SECRETION
*ISLANDS of Langerhans
*CROSS-sectional method
Language
ISSN
1381-3455
Abstract
Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis is not clearly defined. This study aimed to investigate circulating levels of GLP-1 in liver cirrhosis and its association with the severity of liver disease. A total of 80 participants including 39 patients with a definite diagnosis of liver cirrhosis and 41 healthy controls recruited in this cross-sectional study. Circulating levels of GLP-1 were determined using the ELISA method. The severity of liver cirrhosis was assessed according to the Child-Pugh, MELD (i), MELD-Na, MELD New, and UK end-stage liver disease score (UKELD) criteria. The mean age of patients and healthy subjects was 42.51 ± 12.80 and 42.07 ± 10.92 years, respectively (p value =.869). The mean MELD (i), MELD-Na, MELD New, UKELD, and Child-Pugh scores were 14.36 ± 4.26, 15.26 ± 4.81, 14.74 ± 4.66, 52.33 ± 3.82, and 7.28 ± 1.50, respectively. In this study, circulating levels of GLP-1 were statistically lower in cirrhotic patients compared with healthy controls (95.26 ± 17.15 vs 111.84 ± 38.14 pg/mL; p value =.017). Larger prospective studies are needed to explore the incretin effect in cirrhosis patients compared with healthy individuals. [ABSTRACT FROM AUTHOR]